Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30026828 | 1.00 | LRRK2 (0.46) | LRRK2LMNAUSP2CCR5CYP2C9 | |
| SCHEMBL629633 | 0.89 | ALOX5 (0.47) | CYP2C9PTGER1BRD4 | |
| SCHEMBL2993578 | 0.87 | TACR3 (0.46) | LRRK2CYP2C9PTGER1BRD4 | |
| SCHEMBL23541164 | 0.85 | LRRK2 (0.49) | LRRK2LMNAUSP2BRD4 | |
| SCHEMBL32667255 | 0.79 | CYP2C9 (0.47) | LRRK2LMNAUSP2CCR5CYP2C9 | |
| SCHEMBL22412007 | 0.79 | PTGER1 (0.47) | LRRK2LMNAUSP2PTGER1 | |
| SCHEMBL11959262 | 0.78 | BRD4 (0.51) | LRRK2CYP2C9PTGER1BRD4 | |
| SCHEMBL27745072 | 0.78 | LMNA (0.46) | LRRK2LMNAUSP2CCR5PTGER1 | |
| SCHEMBL23270090 | 0.78 | CCR5 (0.46) | LRRK2LMNAUSP2CCR5BRD4 | |
| SCHEMBL31277431 | 0.78 | LRRK2 (0.46) | LRRK2LMNAUSP2CCR5BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116194453-A | Protein tyrosine phosphatase degrading agent and method of use thereof | 卡里科生命科学有限责任公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022271727-A1 | DEGRADER COMPOUNDS AND USES THEREOF | CALICO LIFE SCIENCES LLC (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2021127586-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| US-8252820-B2 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20100197744-A1 | Organic Compounds | BARNES DAVID | 2010-08-05 | — | — | US | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| EP-2155704-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| WO-2008148744-A1 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| EP-1963293-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2 , 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067612-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2, 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197744-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | LRRK2 453/4885LMNA 4846/4885USP2 432/4885 |
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | LRRK2 338/4885LMNA 4839/4885USP2 753/4885 |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | PTPRS, PTPRF, PTPRO | LRRK2 359/4885LMNA 4853/4885USP2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.